文献速递妇科肿瘤

JAVELIN Ovarian 200:avelumab单药或联合化疗对比化疗用于铂耐药或铂难治性卵巢癌的III期研究

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
PubMed 文献 · Lancet Oncol · 2021-06-15

JAVELIN Ovarian 200是一项开放标签、三臂、随机III期试验,在铂耐药或铂难治性卵巢癌患者中比较avelumab单药、avelumab联合聚乙二醇脂质体阿霉素(PLD)与PLD单药的疗效。共566例患者随机分配,主要终点为盲法独立中心评审的无进展生存期和总生存期。结果显示,avelumab联合PLD或avelumab单药均未显著改善无进展生存期或总生存期。

要点

  • avelumab联合PLD或单药对比PLD均未显著改善PFS或OS。
  • 联合组≥3级治疗相关不良事件常见为掌跖红斑感觉异常综合征(10%)。

核心结论

  • avelumab联合PLD或avelumab单药均未显著改善铂耐药或铂难治性卵巢癌患者的无进展生存期或总生存期。

研究设计与样本

  • 开放标签、平行组、三臂、随机III期试验,在24个国家149家医院和癌症治疗中心进行。
  • 纳入566例铂耐药或铂难治性上皮性卵巢癌、输卵管癌或腹膜癌患者,随机1:1:1分配至avelumab联合PLD组(n=188)、PLD组(n=190)或avelumab组(n=188)。
  • 主要终点为盲法独立中心评审的无进展生存期和总生存期,安全性在所有至少接受一剂研究治疗的患者中评估。

主要发现

  • 最常见的≥3级治疗相关不良事件包括掌跖红斑感觉异常综合征(联合组18例[10%] vs PLD组9例[5%] vs avelumab组0例)、皮疹(11例[6%] vs 3例[2%] vs 0例)、疲乏(10例[5%] vs 3例[2%] vs 0例)、口腔炎(10例[5%] vs 5例[3%] vs 0例)、贫血(6例[3%] vs 9例[5%] vs 3例[2%])、中性粒细胞减少(9例[5%] vs 9例[5%] vs 0例)和中性粒细胞计数降低(8例[5%] vs 7例[4%] vs 0例)。

临床怎么用

  • 不推荐在铂耐药或铂难治性卵巢癌中常规使用avelumab单药或avelumab联合PLD。
  • 该结果可为未来免疫检查点抑制剂在铂耐药或铂难治性卵巢癌中的患者选择研究提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy and eventually develop platinum-resistant or platinum-refractory disease. We report results of avelumab alone or avelumab plus pegylated liposomal doxorubicin (PLD) compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer. METHODS: JAVELIN Ovarian 200 was an open-label, parallel-group, three-arm, randomised, phase 3 trial, done at 149 hospitals and cancer treatment centres in 24 countries. Eligible patients were aged 18 years or older with epithelial ovarian, fallopian tube, or peritoneal cancer (maximum of three previous lines for platinum-sensitive disease, none for platinum-resistant disease) and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1:1) via interactive response technology to avelumab (10 mg/kg intravenously every 2 weeks), avelumab plus PLD (40 mg/m2 intravenously every 4 weeks), or PLD and stratified by disease platinum status, number of previous anticancer regimens, and bulky disease. Primary endpoints were progression-free survival by blinded independent central review and overall survival in all randomly assigned patients, with the objective to show whether avelumab alone or avelumab plus PLD is superior to PLD. Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02580058. The trial is no longer enrolling patients and this is the final analysis of both primary endpoints. FINDINGS: Between Jan 5, 2016, and May 16, 2017, 566 patients were enrolled and randomly assigned (combination n=188; PLD n=190, avelumab n=188). At data cutoff (Sept 19, 2018), median duration of follow-up for overall survival was 18·4 months (IQR 15·6-21·9) for the combination group, 17·4 months (15·2-21·3) for the PLD group, and 18·2 months (15·8-21·2) for the avelumab group. Median progression-free survival by blinded independent central review was 3·7 months (95% CI 3·3-5·1) in the combination group, 3·5 months (2·1-4·0) in the PLD group, and 1·9 months (1·8-1·9) in the avelumab group (combination vs PLD: stratified HR 0·78 [repeated 93·1% CI 0·59-1·24], one-sided p=0·030; avelumab vs PLD: 1·68 [1·32-2·60], one-sided p>0·99). Median overall survival was 15·7 months (95% CI 12·7-18·7) in the combination group, 13·1 months (11·8-15·5) in the PLD group, and 11·8 months (8·9-14·1) in the avelumab group (combination vs PLD: stratified HR 0·89 [repeated 88·85% CI 0·74-1·24], one-sided p=0·21; avelumab vs PLD: 1·14 [0·95-1·58], one-sided p=0·83]). The most common grade 3 or worse treatment-related adverse events were palmar-plantar erythrodysesthesia syndrome (18 [10%] in the combination group vs nine [5%] in the PLD group vs none in the avelumab group), rash (11 [6%] vs three [2%] vs none), fatigue (ten [5%] vs three [2%] vs none), stomatitis (ten [5%] vs five [3%] vs none), anaemia (six [3%] vs nine [5%] vs three [2%]), neutropenia (nine [5%] vs nine [5%] vs none), and neutrophil count decreased (eight [5%] vs seven [4%] vs none). Serious treatment-related adverse events occurred in 32 (18%) patients in the combination group, 19 (11%) in the PLD group, and 14 (7%) in the avelumab group. Treatment-related adverse events resulted in death in one patient each in the PLD group (sepsis) and avelumab group (intestinal obstruction). INTERPRETATION: Neither avelumab plus PLD nor avelumab alone significantly improved progression-free survival or overall survival versus PLD. These results provide insights for patient selection in future studies of immune checkpoint inhibitors in platinum-resistant or platinum-refractory ovarian cancer. FUNDING: Pfizer and Merck KGaA, Darmstadt, Germany.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021. PMID: 34143970. doi:10.1016/S1470-2045(21)00216-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。